
Quarterly report 2026-Q1
added 05-08-2026
Inogen Revenue 2011-2026 | INGN
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Inogen
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 349 M | 336 M | 316 M | 377 M | 358 M | 308 M | 362 M | 358 M | 249 M | 203 M | 159 M | 113 M | 75.4 M | 48.6 M | 30.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 377 M | 30.6 M | 243 M |
Quarterly Revenue Inogen
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 85.1 M | 92.4 M | 92.3 M | 82.3 M | - | 88.8 M | 88.8 M | 78 M | - | 84 M | 83.6 M | 72.2 M | - | 105 M | 103 M | 80.4 M | - | 93.1 M | 102 M | 86.9 M | 74 M | 74.3 M | 71.7 M | 88.5 M | 78.9 M | 91.8 M | 101 M | 90.2 M | 86.5 M | 95.3 M | 97.2 M | 73.6 M | 63.8 M | 63.1 M | 58 M | 46 M | 50.9 M | 47.2 M | 45.6 M | 32.8 M | 40.4 M | 29.2 M | 32.4 M | 23 M | 29.1 M | 19.4 M | 20.5 M | 14.9 M | 19.8 M | 12.1 M | 12.8 M | 8.9 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 105 M | 8.9 M | 64.8 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
366 M | - | - | $ 3.31 B | ||
|
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
ClearPoint Neuro
CLPT
|
37 M | $ 11.82 | 3.32 % | $ 335 M | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
Alphatec Holdings
ATEC
|
764 M | $ 8.06 | -2.54 % | $ 1.21 B | ||
|
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | ||
|
EDAP TMS S.A.
EDAP
|
64.1 M | $ 4.31 | 0.23 % | $ 161 M | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
Helius Medical Technologies
HSDT
|
6.02 M | $ 2.3 | 0.44 % | $ 50.7 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
IRIDEX Corporation
IRIX
|
52.7 M | $ 1.04 | 2.97 % | $ 17.6 M | ||
|
Cytosorbents Corporation
CTSO
|
37.1 M | $ 0.46 | 0.39 % | $ 28.6 M | ||
|
OrthoPediatrics Corp.
KIDS
|
236 M | $ 17.9 | -2.56 % | $ 420 M | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 10.83 | -1.72 % | $ 388 M | ||
|
LENSAR
LNSR
|
58.4 M | $ 6.05 | -0.66 % | $ 72.3 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
LivaNova PLC
LIVN
|
1.39 B | $ 75.42 | 2.15 % | $ 4.11 B | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Pulmonx Corporation
LUNG
|
90.5 M | $ 1.57 | 1.29 % | $ 63.9 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
MiMedx Group
MDXG
|
419 M | $ 3.67 | 1.38 % | $ 542 M | ||
|
Electromed
ELMD
|
64 M | $ 38.3 | 0.21 % | $ 324 M | ||
|
Myomo
MYO
|
40.9 M | $ 1.03 | -0.96 % | $ 43.1 M | ||
|
Butterfly Network
BFLY
|
97.6 M | $ 4.54 | 1.68 % | $ 1.12 B | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
Orthofix Medical
OFIX
|
822 M | $ 9.77 | -9.12 % | $ 387 M | ||
|
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | ||
|
Globus Medical
GMED
|
2.94 B | $ 85.1 | 0.34 % | $ 11.5 B | ||
|
Profound Medical Corp.
PROF
|
16.1 M | $ 6.77 | -0.88 % | $ 205 M | ||
|
Insulet Corporation
PODD
|
2.71 B | $ 153.8 | -0.69 % | $ 10.8 B | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 36.06 | -3.14 % | $ 1.12 B | ||
|
Sintx Technologies
SINT
|
1.02 M | $ 2.43 | 1.67 % | $ 6.74 M | ||
|
Inspire Medical Systems
INSP
|
912 M | $ 41.99 | -4.22 % | $ 1.23 B | ||
|
Integer Holdings Corporation
ITGR
|
1.85 B | $ 90.14 | 0.96 % | $ 3.13 B | ||
|
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
6.07 B | $ 87.54 | 2.05 % | $ 51.2 B | ||
|
TransMedics Group
TMDX
|
605 M | $ 70.46 | 2.21 % | $ 2.4 B |